GlassScriptPhysician profile
Ernesto J Lamadrid
NPI 1578777140
$128,085.33
in general payments reported to CMS, 2019-2025
32 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $27K · 2021: $37K · 2022: $50K · 2023: $154 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $75,479.83 | 2019-2025 | Dovato |
| Gilead Sciences, INC. | $22,643.04 | 2019-2023 | Biktarvy |
| Merck Sharp & Dohme LLC | $22,253.46 | 2019-2022 | |
| Abbvie INC. | $2,674.43 | 2019-2022 | |
| Janssen Biotech, INC. | $752.07 | 2019-2023 | Symtuza |
| Sanofi-Aventis U.S. LLC | $739.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $487.56 | 2019-2022 | |
| Lilly USA, LLC | $430.00 | 2019-2022 | |
| Novo Nordisk INC | $405.59 | 2019-2022 | |
| Napo Pharmaceuticals INC | $345.52 | 2019-2025 | Mytesi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.97 | 2019-2022 | |
| Theratechnologies INC. | $226.70 | 2019-2022 | |
| Janssen Products, LP | $199.90 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $194.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.25 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $160.49 | 2019-2022 | |
| Amgen INC. | $99.83 | 2020-2022 | |
| Glaxosmithkline, LLC. | $97.70 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $75.51 | 2019 | |
| Nestle Healthcare Nutrition INC. | $63.40 | 2021-2022 | |
| Smith+Nephew, INC. | $55.25 | 2019-2022 | |
| Allergan, INC. | $49.12 | 2019-2020 | |
| Emd Serono, INC. | $45.76 | 2020-2022 | |
| Octapharma USA, INC. | $30.25 | 2020 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Abbott Laboratories | $22.93 | 2022 | |
| Horizon Therapeutics Plc | $17.63 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.06 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.56 | 2020 | |
| Mylan Specialty L.P. | $15.16 | 2020 | |
| Kvk-Tech, INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernesto Lamadrid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.